Thalia Therapeutics Plc (THAT.L)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | £m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | £m | -1 | -1 | ||||||
| Net profit | £m | -1 | -2 | -1 | -1 | -1 | -1 | -1 | - |
| EPS reported | £ | -0.00 | -0.00 | ||||||
| Operating cashflow per share | £ | -0.00 | -0.00 | ||||||
| Capex per share | £ | 0.00 | 0.00 | ||||||
| FCF per share | £ | -0.00 | -0.00 | ||||||
| Free cash flow | £m | -1 | -1 | ||||||
| Net debt | £m | -1 | -1 | ||||||
| Book value equity | £m | 1 | 1 | ||||||
| Book value per share | £ | 0.00 | 0.00 | ||||||
| Number of shares | m | 724.4 | 832.28 | ||||||
| DPS (TTM paid) | £ | 0.00 | 0.00 |
Financial summary
Financials in GBP| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 3.55 | 3.55 | ||||||
| P/S LTM | x | 523.56 | 523.56 | ||||||
| P/FCF LTM | x | -3.28 | -3.28 | ||||||
| EV/EBITDA LTM | x | -2.47 | -2.47 | ||||||
| EV/Sales LTM | x | 374.97 | 624.80 | ||||||
| Earnings Yield LTM | % | -31.69% | -21.45% | ||||||
| FCF Yield | % | -30.53% | -30.53% | ||||||
| Quality | |||||||||
| ROE | % | -112.64% | -84.97% | ||||||
| ROIC | % | -1.03% | -1.03% | ||||||
| Operating margin | % | -152.00% | -152.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | -15985.13% | -15985.27% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | -0.25% | -0.25% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | - | - | ||||||
| Net Debt/EBITDA | x | 0.98 | 0.98 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | 0.00% | 0.00% | ||||||
| Net debt/Equity | x | -1.01 | -1.01 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Thalia Therapeutics Plc, a specialized pharmaceutical company established in 1979 and headquartered in Chellaston, UK, focuses on developing advanced nanoparticle silica delivery systems. These innovative systems are designed to enhance the cellular uptake and effectiveness of various cancer treatments and vaccines. The company's product portfolio includes Nuvec, a unique silica nanoparticle delivery platform distinguished by its irregular surface structure that effectively encapsulates and safeguards genetic material such as siRNA, RNA, and DNA. Additionally, it offers Liptide, a specialized platform engineered for the targeted delivery of a proprietary siRNA sequence to silence fibrotic genes. Thalia Therapeutics is also advancing N4 101, an orally administered inflammation inhibitor currently undergoing pre-clinical evaluation for the treatment of inflammatory bowel disease, alongside ECP105, which is being developed to prevent ocular scarring. The firm, previously known as N4 Pharma Plc, officially rebranded to Thalia Therapeutics Plc in March 2026.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free